CCNE1 and endometrial cancer: CCNE1 is amplified in 8% of endometrial endometrioid adenocarcinomas (EMCAs), 45% of uterine carcinosarcomas, and 50% of serous EMCAs, particularly in high-grade serous ovarian cancer (HGSOC) and endometrial cancer (EC) [3–6].